Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 4/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | MC5R | P33032 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258784 | 0.80 | FLT3 (0.45) | FLT3ASIC3APPCYP1A2CYP2C9 | |
| SCHEMBL17459806 | 0.78 | FLT3 (0.47) | FLT3 | |
| SCHEMBL19006332 | 0.76 | FLT3 (0.43) | FLT3 | |
| SCHEMBL17469773 | 0.73 | FLT3 (0.52) | FLT3 | |
| SCHEMBL17469783 | 0.73 | FLT3 (0.52) | FLT3ASIC3 | |
| SCHEMBL17469805 | 0.72 | FLT3 (0.71) | FLT3ASIC3HSD17B10 | |
| SCHEMBL7258744 | 0.66 | KDM4E (0.42) | KCNH2CYP1A2CYP2D6HSD17B10 | |
| SCHEMBL23599995 | 0.65 | ATR (0.48) | HSD17B10 | |
| SCHEMBL21102878 | 0.64 | FLT3 (0.73) | FLT3 | |
| SCHEMBL7253831 | 0.64 | KDM4E (0.46) | FLT3CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | FLT3 2354/4885ROCK1 3419/4885ASIC3 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.